Deutsch
 
Hilfe Datenschutzhinweis Impressum
  DetailsucheBrowse

Datensatz

DATENSATZ AKTIONENEXPORT
Zur Ablage hinzufügen
  Lokale TagsFreigabegeschichteDetailsÜbersicht

Freigegeben
Zeitschriftenartikel

Alzheimer’s disease FDG PET imaging pattern in an amyloid-negative mild cognitive impairment subject

MPG-Autoren
/persons/resource/persons19981

Schroeter,  Matthias L.
Clinic for Cognitive Neurology, University of Leipzig, Germany;
Department Neurology, MPI for Human Cognitive and Brain Sciences, Max Planck Society;
Leipzig Research Center for Civilization Diseases (LIFE), University of Leipzig, Germany;

Externe Ressourcen
Es sind keine externen Ressourcen hinterlegt
Volltexte (beschränkter Zugriff)
Für Ihren IP-Bereich sind aktuell keine Volltexte freigegeben.
Volltexte (frei zugänglich)
Es sind keine frei zugänglichen Volltexte in PuRe verfügbar
Ergänzendes Material (frei zugänglich)
Es sind keine frei zugänglichen Ergänzenden Materialien verfügbar
Zitation

Tiepolt, S., Patt, M., Hoffmann, K.-T., Schroeter, M. L., Sabri, O., & Barthel, H. (2015). Alzheimer’s disease FDG PET imaging pattern in an amyloid-negative mild cognitive impairment subject. Journal of Alzheimer's Disease, 47(3), 539-543. doi:10.3233/JAD-150163.


Zitierlink: https://hdl.handle.net/11858/00-001M-0000-0029-ACB8-6
Zusammenfassung
The revised NIA-AA diagnostic criteria for Alzheimer’s disease (AD) and mild cognitive impairment (MCI) due to AD make use of amyloid pathology and neurodegeneration biomarkers which increase the diagnostic confidence in the majority of patients. However, in daily praxis, cases with conflicting biomarker constellations occur. A MCI subject underwent neuropsychological testing supplemented by FDG and amyloid PET/MRI as well as CSF sampling. In this subject, the biomarkers of Aβ deposition were negative. [18F]FDG PET, however, showed an AD-typical hypometabolism. Further studies are required to determine frequency and relevance of cases with neurodegeneration-first biomarker constellations to improve our understanding on pathogenesis and diagnosis of AD.